Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.09.2013 | main topic

Bone turnover in hyperparathyroidism

verfasst von: Katharina Kerschan-Schindl, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 17-18/2013

Einloggen, um Zugang zu erhalten

Summary

A narrow serum calcium level which is essential for many metabolic processes is regulated by the calcium-sensing receptor which regulates parathyroid hormone (PTH) release. Primary hyperparathyroidism is supposed to be the third most common endocrine disorder. Besides nephrolithiasis and an increased incidence of cardiovascular symptoms it is associated with bone loss and an increased risk of fracture. Several different classical bone turnover markers have been shown to be increased. However, there are many uncertainties in pathophysiology of PHPT. Hardly any conclusive data exist on the RANK (receptor activator of nuclear factor-kB)/RANKL (receptor activator of nuclear factor-kB ligand)/OPG (osteoprotegerin) system, cathepsin K, sclerostin, FGF-23 (Fibroblast growth factor-23), Klotho, and DKK 1 (Dickkopf 1) in patients suffering from PHPT.
Vorheriger Artikel Hyperparathyroidism
Nächster Artikel Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy
Literatur
1.
Melton LJ III. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17(Suppl 2):12–17.
2.
Wermers RA, Koshla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2011: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21:171–7.PubMedCrossRef
3.
Eriksen EF, Mosekilde L, Melsen F. Bone remodeling and balance in primary hyperparathyroidism. Bone. 1986;7:213–21.PubMedCrossRef
4.
Pietschmann P, Niederle B, Anvari A, et al. Serum osteocalcin levels in primary hyperparathyroidism. Klin Wochenschr. 1991;69:351–3.PubMedCrossRef
5.
Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88:4655–8.PubMedCrossRef
6.
Khosla S, Melton LJ III, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14:1700–7.PubMedCrossRef
7.
Vestergaard P, Mollerup CL, Frokjaer V, et al. Chort study of risk of fracture before and after surgery for primary hyperparathyroidism. Br Med J. 2000;321:598–602.CrossRef
8.
Seibl MJ, Gartenberg F, Silverberg SJ, et al. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab. 1992;74:481–6.CrossRef
9.
Guo CY, Thomas WEG, Al-Dehaimi AW, et al. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:3487–91.PubMedCrossRef
10.
Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone. 1997;21:93–9.PubMedCrossRef
11.
Suzuki S, Fukushima T, Ami H, et al. Pre- and postoperative bone metabolism of primary hyperparathyroidism. Biomed Pharmacoth. 2000;54(Suppl 1):90–96.CrossRef
12.
Abe Y, Ejima E, Fujiyama K, et al. Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones. Clin Endocrinol. 2000;52:203–9.CrossRef
13.
Guo CY, Holand PA, Jackson BF, et al. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol. 2000;142:451–9.PubMedCrossRef
14.
Nakaoka D, Sugimoto T, Kobayashi T, et al. Evaluation of changes in bone density and biochemical parameters after parathyroidectomy in primary hyperparathyroidism. Endocrine Journal. 2000;47:231–7.PubMedCrossRef
15.
Christiansen P, Steiniche T, Vesterby A, et al. Primary hyperparathyroidism: iliac crest trabecular boen volume, structure, remodeling, and balance evaluated by histomorphometric methods. Bone. 1992;13:41–9.PubMedCrossRef
16.
Thorsen K, Kristoffersson AO, Lorentzon RP. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery. 1997;122:882–7.PubMedCrossRef
17.
Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: short term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone. 1999;25:237–44.PubMedCrossRef
18.
Cortet B, Cortet C, Blanckaert F, et al. Bone ultrasonometry and turnover markers in primary hyperparathyroidism. Calcif Tissue Int. 2000;66:11–5.PubMedCrossRef
19.
Steiniche T, Christiansen P, Vesterby A, et al. Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone. 2000;26:535–43.PubMedCrossRef
20.
Carnevale V, Pacitti MT, Pileri M, et al. Short-term effects of surgery in post-menopausal patients with primary hyperparathyroidism and normal bone turnover. Endocrinol Invest. 2001;24:575–9.
21.
Lumachi F, Ermani M, Basso SMM, et al. Short- and long-term changes in bone mineral density of the lumbar spine after parathyroidectomy in patients with primary hyperparathyroidism. Calcif Tissue Int. 2003;73:44–8.PubMedCrossRef
22.
Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol. 2007;143:31–48.PubMedCrossRef
23.
Piedra M, Garcia-Unzueta MT, Berja A, et al. Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with boen mineral density. BMC Med Genet. 2011;12:168–76.PubMedCrossRef
24.
Fraher U, Watson PH, Kisiel M, et al. Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH (1–34). 2000; ASBMR, Toronto (abstract).
25.
Nakchbandi IA, Lang R, Kinder B, et al. The role of the receptor activator of nuclear factor-kB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008;93:967–73.PubMedCrossRef
26.
Stilgren LS, Hegedüs LM, Beck-Nielsen H, et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int. 2003;73:210–216.PubMedCrossRef
27.
Kerschan-Schindl K, Riss P, Krestan C, et al. Bone metabolism in patients with primary hyperparathyroidism before and after surgery. Horm Metab Res. 2012;44:1–6.CrossRef
28.
Stilgren LS, Rettmer E, Hegedüs LM, et al. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kB ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone. 2004;35:256–65.PubMedCrossRef
29.
Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146:4577–83.PubMedCrossRef
30.
O’Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008;3:e2942 (Zit 8 von Van Lierop AH et al Eur J Endocrinol 2010;163:833–837).PubMedCrossRef
31.
Kaji H, Imanishi Y, Sugimoto T, Seino S. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes. 2011;119:440–4.PubMedCrossRef
32.
Van Lierop AH, Witteveen JE, Handy NAT, et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol. 2010;163:833–7.PubMedCrossRef
33.
Ardawi MSM, Al-Sibiany AM, Bakhsh TM, et al. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int. 2011;23(6):1789–97.PubMedCrossRef
34.
Munoz-Torres M, Reyes-Garcia R, Mezquita-Raya P, et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with a Alendronate. Maturitas. 2009;64:188–92.PubMedCrossRef
35.
Gupta A, Winer K, Econs MJ, et al. FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab. 2004;89:4489–92.PubMedCrossRef
36.
Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol. 2004;151:55–60.PubMedCrossRef
37.
Kobayashi K, Imanishi Y, Miyauchi A, et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2006;154:93–9.PubMedCrossRef
38.
Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulated fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18:2683–8.PubMedCrossRef
39.
Björklund P, Krajisnik T, Akerström G, et al. Type I Membrane Klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008;93:4152–7.PubMedCrossRef
40.
Guo J, Liu M, Yand D, et al. Suppression of Wnt signaling by Dkk1 attenuated PTH-mediated stromal cell response and new bone formation. Cell Metabolism. 2010;11:161–71.PubMedCrossRef
41.
Bilezikian JP, Khan AA, Potts JT. On behalf of the third international workshop on the management of asymptomatic primary hyperparathyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international Workshop. J Clin Endocrinol Metab. 2009;94:335–9.PubMedCrossRef
42.
Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol. 2002;146:783–8.PubMedCrossRef
43.
Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: effect of parathyroidectomy on regional boen mienral density in Danish patients: a three-year follow-up study. Bone. 1999;25:589–95.PubMedCrossRef
44.
Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:729–34.PubMedCrossRef
45.
Marocci C, Cetami F. Primary hyperparathyroidism. N Engl J Med. 2011;365:2389–97.CrossRef
46.
Kahn AA, Bilezikian JP, Kung AWC, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319–25.CrossRef
47.
Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized, controlled trial. Ann Int Med. 1996;125:360–8.PubMedCrossRef
48.
Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477–501.PubMedCrossRef
49.
Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–21.PubMedCrossRef
50.
Ekoyan G, Levin A, Levin NW. K/DOIQI clinical practice guidelines on bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:12–28, 52–57.CrossRef
51.
Okada M, Tominaga Y, Izumi K, et al. Tertiary hyperparathyroidism resistant o cinacalcet treatment. Ther Apher Dial. 2011;15(Suppl 1):33–7.PubMedCrossRef
Metadaten
Titel
Bone turnover in hyperparathyroidism
verfasst von
Katharina Kerschan-Schindl, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 17-18/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-012-0125-9

Weitere Artikel der Ausgabe 17-18/2013

Renale Osteodystrophie

  • main topic

Congenital complete and partial absence of the left pericardium

  • short communication

Die Elektropathologie in Wien – eine Sammlung zur Unfallverhütung

  • bericht

Hyperparathyroidism

  • editorial

Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy

  • main topic

Internationaler Status Dickdarmkrebs-Screening und Qualitätssicherung der Screening-Koloskopie

  • originalarbeit